New Chair-Based Therapy Aims to Break the Silence on Pelvic Health

CLEARWATER, FL – March 31, 2026 – Millions of people experience bladder leakage and pelvic floor weakness, often suffering in silence. Today, Bedrock Bioscience introduced a new contender in the battle for better pelvic health: the Gazelle™ Chair, a device promising a non-invasive solution to a deeply personal problem.

The company announced the launch of its FDA-cleared medical device, designed to strengthen the pelvic floor muscles that are crucial for bladder control and core stability. The treatment aims to address common issues like stress incontinence—leakage when coughing or laughing—frequent urination, and weakness following childbirth, without surgery, drugs, or downtime.

The Science of a Seated Solution

At the heart of the Gazelle™ Chair is a technology known as Extracorporeal Magnetic Innervation, or ExMI. While presented as a new breakthrough, the underlying science has been explored for over two decades. The technology uses powerful, focused magnetic pulses to stimulate the nerves deep within the pelvic floor. This process triggers thousands of involuntary muscle contractions—far more than one could achieve with traditional Kegel exercises.

During a typical 20-minute session, a patient sits fully clothed on the chair while the device works. Bedrock Bioscience claims the chair delivers a high number of "supramaximal" contractions, effectively re-educating and strengthening the muscles that support the bladder and other pelvic organs. Immediately after the session, patients can return to their daily activities.

This non-invasive approach has gained traction in recent years, offering a stark contrast to more invasive options. The technology has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), classifying it as a Class II Power Muscle Stimulator, a category that signals a moderate risk profile and requires regulatory oversight to ensure safety and effectiveness.

A Crowded Market for a Common Condition

The launch comes at a time of significant growth and innovation in the pelvic health sector. The global market for pelvic floor dysfunction treatments is projected to climb from USD 1.68 billion in 2026 to nearly USD 2.8 billion by 2035. This boom is fueled by an aging population and a growing willingness to discuss and treat conditions that were once considered taboo.

"This is about giving people their lives back," said a Gazelle™ Chair provider quoted in the company's announcement. "When patients can move, sleep, and live without constantly thinking about their symptoms, it changes everything."

The Gazelle™ Chair enters a competitive landscape that includes a wide array of solutions. Traditional first-line treatments include specialized physical therapy and diligent at-home Kegel exercises. The market also features other high-tech devices, from biofeedback trainers like the Elvie Trainer to other chair-based systems using similar electromagnetic technology, such as the Emsella chair. Beyond devices, treatment options extend to pharmaceuticals for urge incontinence and surgical procedures like bladder slings for more severe cases of stress incontinence.

Bedrock Bioscience is positioning the Gazelle™ Chair as a comfortable and convenient alternative that bridges the gap between ineffective exercises and invasive surgery, offering a solution for those who have delayed care or discontinued other treatments.

Evaluating the Evidence and Experience

Bedrock Bioscience states its technology is backed by over 40 clinical studies and cites a peer-reviewed article from 2000 that demonstrated the effectiveness of chair-based ExMI for stress urinary incontinence. Indeed, the technology has been the subject of research for many years, with some studies showing promising results.

However, the broader medical community continues to evaluate its precise place in treatment protocols. A comprehensive systematic review published in 2023, which analyzed over a decade of randomized clinical studies on ExMI, concluded that while the technology shows promise, more robust and standardized research is needed before it can be cemented as a standard of care. Some literature even suggests that dedicated pelvic floor muscle training under a physical therapist can be just as effective.

Furthermore, while the company's press release emphasizes a comfortable, pain-free experience, the broader research on ExMI technology presents a more nuanced picture. One study highlighted in a recent review reported that a significant percentage of participants withdrew from therapy due to side effects, including leg and back pain, tingling sensations, and other discomforts. This suggests that while many patients may find the treatment tolerable, individual experiences can vary, and it may not be entirely without side effects for everyone.

Access, Cost, and the Path Forward

For the Gazelle™ Chair to make a significant impact, it must be accessible to both patients and providers. For clinics, medspas, and physical therapy practices, acquiring the device represents a substantial investment, with pricing structures involving a down payment and monthly installments reportedly starting at $2,000. This cost could be a barrier for smaller practices, potentially limiting the treatment's availability.

However, for the clinics that do invest, the chair's automated, hands-free operation offers a potential benefit by allowing them to offer a consistent, measurable therapy without increasing staff workload. As this technology becomes more available through select providers nationwide, its real-world effectiveness and patient satisfaction rates will become clearer.

The introduction of the Gazelle™ Chair adds another promising, high-tech option to a diverse and rapidly evolving field of pelvic health. Its success will ultimately depend on its ability to deliver consistent, lasting results that justify its cost for both providers and the patients seeking to regain control and improve their quality of life.